Table 4.
Combination of genes and clinical risk factors | Sensitivity | Specificity | Accuracy | AUC | ORIQR | p |
---|---|---|---|---|---|---|
SNORD99 | 0.667 | 0.625 | 0.654 | 0.681 | 0.384 | 0.0426 |
SNORD22 | 0.500 | 0.875 | 0.629 | 0.704 | 0.560 | 0.0375 |
SNORD26 | 0.761 | 0.667 | 0.729 | 0.677 | 0.573 | 0.0578 |
SNORA50C | 0.778 | 0.667 | 0.744 | 0.735 | 0.210 | 0.0108 |
SNORD99 + OBS + HTN | 0,900 | 0,417 | 0,743 | 0,693 | 0.385 | 0.0657 |
SNORD22 + OBS + HTN | 0,791 | 0,667 | 0,746 | 0,733 | 0.570 | 0.0586 |
SNORD26 + OBS + HTN | 0,628 | 0,750 | 0,672 | 0,720 | 0.541 | 0.0495 |
SNORA50C + OBS + HTN | 0,840 | 0,625 | 0,770 | 0,766 | 0.165 | 0.0046 |
The expression values of the genes validated with qPCR were used in the regression models alone or in combination with obesity (OBS; BMI ≥ 30) and hypertension (HTN) as clinical risk factors. All models were adjusted for age and gender. The p-values of the top four results are those of the genes in the models (association with the response). The p-values of the bottom four results are those of the overall model fit (chi-squared test against the null model). P-values < 0.05 are shown in bold. Odds ratios (OR) for the risk of ccRCC presence were calculated on the basis of a gene expression change in the size of the interquartile range (IQR) of the respective gene